泰坦制药 TTNP 深 沪
已收盘 10-01 16:00:00 美东时间
4.61
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 4.61
- 总市值 613.22万
- 52周最高 5.76
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.03
- 委 比 0.00%
- 总股本 133.02万
- 历史最高 36000.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 3.03
- 每 手 1
- 风险率 1.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Titan Pharmaceuticals Undergoes Leadership Restructuring
An update from Titan Pharmaceuticals ( ($TTNP) ) is now available. On October 1...
10-02 04:51
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Check-Cap (NASDAQ:CHEK) stock rose 25.5% to $2.66 during Monday's afte...
09-16 05:06
BioXcel Stock Surges 19% In After-Hours Trading: What You Need To Know
BioXcel Therapeutics shares surged over 19% after hours ahead of key Phase 3 trial results for its at-home agitation treatment, sparking strong investor interest.
08-27 14:55
Titan Pharmaceuticals Approves Merger with Black Titan
Titan Pharmaceuticals ( ($TTNP) ) just unveiled an update. On August 26, 2025, ...
08-27 04:32
Titan Pharmaceuticals Announces Merger with Black Titan
New activity is brewing for Titan Pharmaceuticals ( ($TTNP) ). The company has ...
07-23 05:33
Titan Pharmaceuticals Completes Securities Purchase Agreement
Titan Pharmaceuticals ( ($TTNP) ) just unveiled an update. On June 24, 2025, Ti...
06-28 04:59
Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock
Titan Pharmaceuticals announced the completion of a private placement of 60,000 shares of its Series C Convertible Preferred Stock to Blue Harbour Asset Management for $600,000 at a conversion price of $3.40. The transaction includes a beneficial ownership blocker limiting Blue Harbour to a maximum of 19.99% of the Company's outstanding common stock. The shares were sold under Regulation S and are subject to a registration rights agreement. Addit...
06-27 20:05
Titan Pharmaceuticals Announces Filing By Black Titan Corporation With SEC For Previously Announced Proposed Combination Of Titan And TalenTec
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission ("SEC") of a registration statement on Form F-4
06-03 20:49
Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.
Titan Pharmaceuticals and TalenTec have entered into a Merger Agreement for a "reverse merger" transaction. Black Titan Corporation filed a Form F-4 with the SEC, including a preliminary proxy statement, in connection with the proposed combination. The transaction requires approval from Titan's stockholders and is expected to close in the third quarter of 2025, subject to customary closing conditions. Investors are advised to review the prelimina...
06-03 12:45
Titan Pharmaceuticals announces $1 million private placement
Titan Pharmaceuticals (NASDAQ:TTNP) announced on Friday that it has completed a private placement of the company’s newly designated Series B convertible preferred stock with Blue Harbour Asset Managem...
04-12 04:41
